BioSpace News Archive

ASLAN Pharmaceuticals today announced that four abstracts on eblasakimab and farudodstat have been accepted for e-poster and oral presentations at the 32nd European Academy of Dermatology and Venereology (EADV), taking place from October 11 to 14, 2023, in Berlin, Germany.

PolyPid Ltd. today announced that Company’s management will present at the Cantor Global Healthcare Conference taking place on September 26-28, 2023, in New York City, New York. Cantor Global Healthcare Conference.

TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the 2023 Cantor Global Healthcare Conference, being held at the Intercontinental Barclay Hotel, in New York City on September 26 - 28, 2023.

Positive high-level results from the TROPION-Breast01 Phase III trial showed datopotamab deruxtecan (Dato-DXd) demonstrated a statistically significant and clinically meaningful improvement for the primary endpoint of progression-free survival (PFS).

Neoleukin Therapeutics, Inc., today announced that its Board of Directors (“Board”) has approved a reverse stock split of the Company’s outstanding shares of common stock at a ratio of 1-for-5.

Fulcrum Therapeutics, Inc. ® today announced that management will participate in a fireside chat at the Cantor Fitzgerald Global Healthcare Conference, being held in New York, NY on Thursday, September 28, 2023 at 8:35 a.m. ET.

Dilon Technologies Inc. announced today the publication of Cost Minimization in Breast Conserving Surgery: A Comparative Study of Radiofrequency Spectroscopy and Full Cavity Shave Margins for Patients Undergoing Breast Conserving Surgery, in the Journal of Cost Effectiveness and Resource Allocation.

Alzamend Neuro, Inc. today announced that it received notice from the Nasdaq Hearings Panel (the “ Hearings Panel ”) of The Nasdaq Stock Market LLC (“ Nasdaq ”), which granted Alzamend’s request for continued listing on The Nasdaq Capital Market, subject to Alzamend’s satisfaction of the minimum $1.00 bid price requirement by November 15, 2023.

Graf Acquisition Corp. IV (NYSE: GFOR, GFOR.U, GFOR WS) (the “Company” or “Graf”), announced today that on September 20, 2023 , it adjourned, without conducting any business, the special meeting of its stockholders to be held to approve, among other things, the previously announced business combination with NKGen Biotech, Inc.

Each week more than 3 million radiographic exams are carried out with Agfa equipment around the world.